XENE insider transaction filings
Xenon Pharmaceuticals Inc. — 38 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-13. Screen XENE transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-13 | 4 | GANNON STEVEN — Director | Sale (S): 10,000 @ $64.06 | EDGAR |
| 2026-06-08 | 4 | Cannon Gillian — Director | Sale (S): 1,190 @ $53.14 | EDGAR |
| 2026-06-08 | 4 | PATOU GARY — Director | Sale (S): 1,322 @ $53.14 | EDGAR |
| 2026-06-03 | 4 | Gover Justin D. — Director | Option exercise (M): 2,645 · Option exercise (M): 2,645 (derivative) @ $0 · Grant/award (A): 10,507 (derivative) @ $0 · Grant/award (A): 1,593 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | GAROFALO ELIZABETH A. — Director | Option exercise (M): 2,645 · Option exercise (M): 2,645 (derivative) @ $0 · Grant/award (A): 10,507 (derivative) @ $0 · Grant/award (A): 1,593 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | GANNON STEVEN — Director | Option exercise (M): 2,645 · Tax withholding (F): 1,416 @ $53.41 · Option exercise (M): 2,645 (derivative) @ $0 · Grant/award (A): 10,507 (derivative) @ $0 · Grant/award (A): 1,593 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Cannon Gillian — Director | Option exercise (M): 2,645 · Option exercise (M): 2,645 (derivative) @ $0 · Grant/award (A): 10,507 (derivative) @ $0 · Grant/award (A): 1,593 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Svoronos Dawn — Director | Option exercise (M): 2,645 · Tax withholding (F): 1,416 @ $53.41 · Option exercise (M): 2,645 (derivative) @ $0 · Grant/award (A): 10,507 (derivative) @ $0 · Grant/award (A): 1,593 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Machado Patrick — Director | Option exercise (M): 2,645 · Option exercise (M): 2,645 (derivative) @ $0 · Grant/award (A): 10,507 (derivative) @ $0 · Grant/award (A): 1,593 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | PATOU GARY — Director | Option exercise (M): 2,645 · Option exercise (M): 2,645 (derivative) @ $0 · Grant/award (A): 10,507 (derivative) @ $0 · Grant/award (A): 1,593 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | GANNON STEVEN — Director | Option exercise (M): 3,500 @ $7.38 · Option exercise (M): 3,500 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | KENNEY CHRISTOPHER JOHN — Chief Medical Officer | Option exercise (M): 3,750 · Sale (S): 1,410 @ $55.23 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | DiFabio Andrea — Chief Legal Officer | Option exercise (M): 3,750 · Sale (S): 1,342 @ $55.23 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | MORTIMER IAN — PRESIDENT & CEO, Director | Option exercise (M): 12,500 · Sale (S): 7,308 @ $55.23 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | KENNEY CHRISTOPHER JOHN — Chief Medical Officer | Option exercise (M): 7,500 · Sale (S): 2,771 @ $60.11 · Grant/award (A): 7,500 (derivative) @ $0 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | DiFabio Andrea — Chief Legal Officer | Option exercise (M): 7,500 · Sale (S): 2,607 @ $60.11 · Grant/award (A): 7,500 (derivative) @ $0 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | MORTIMER IAN — PRESIDENT & CEO, Director | Option exercise (M): 75,000 @ $8.40 · Sale (S): 21,791 @ $58.81 · Sale (S): 31,694 @ $59.88 · Sale (S): 21,515 @ $60.49 · Option exercise (M): 25,000 @ $3.10 · Sale (S): 12,479 @ $59.50 · +15 more | EDGAR |
| 2026-01-09 | 4 | KENNEY CHRISTOPHER JOHN — Chief Medical Officer | Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Cline Darren S — Chief Commercial Officer | Grant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | DiFabio Andrea — Chief Legal Officer | Grant/award (A): 80,000 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | MORTIMER IAN — PRESIDENT & CEO, Director | Grant/award (A): 350,000 (derivative) @ $0 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | MORTIMER IAN — PRESIDENT & CEO, Director | Option exercise (M): 40,000 @ $7.49 · Sale (S): 37,938 @ $44.40 · Sale (S): 2,062 @ $44.93 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | MORTIMER IAN — PRESIDENT & CEO, Director | Sale (S): 14,375 @ $45.03 · Sale (S): 8,820 @ $45.59 · Sale (S): 2,010 @ $46.32 | EDGAR |
| 2025-12-03 | 4 | MORTIMER IAN — PRESIDENT & CEO, Director | Sale (S): 97 @ $45.01 | EDGAR |
| 2025-10-17 | 4 | Kelly Thomas Patrick — Chief Financial Officer | Grant/award (A): 225,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | MORTIMER IAN — PRESIDENT, CEO & INTERIM CFO, Director | Option exercise (M): 25,000 @ $7.69 · Sale (S): 25,000 @ $40.16 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Cline Darren S — Chief Commercial Officer | Grant/award (A): 185,800 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Gover Justin D. — Director | Grant/award (A): 17,012 (derivative) @ $0 · Grant/award (A): 2,645 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | GAROFALO ELIZABETH A. — Director | Grant/award (A): 17,012 (derivative) @ $0 · Grant/award (A): 2,645 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | GANNON STEVEN — Director | Sale (S): 3 @ $30.48 · Grant/award (A): 17,012 (derivative) @ $0 · Grant/award (A): 2,645 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Cannon Gillian — Director | Grant/award (A): 17,012 (derivative) @ $0 · Grant/award (A): 2,645 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Svoronos Dawn — Director | Grant/award (A): 17,012 (derivative) @ $0 · Grant/award (A): 2,645 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Machado Patrick — Director | Grant/award (A): 17,012 (derivative) @ $0 · Grant/award (A): 2,645 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | PATOU GARY — Director | Grant/award (A): 17,012 (derivative) @ $0 · Grant/award (A): 2,645 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | GANNON STEVEN — Director | Option exercise (M): 5,144 @ $12.57 · Option exercise (M): 5,144 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | MORTIMER IAN — PRESIDENT & CEO, Director | Grant/award (A): 275,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | KENNEY CHRISTOPHER JOHN — Chief Medical Officer | Grant/award (A): 80,000 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-03-13 | 4 | DiFabio Andrea — Chief Legal Officer | Grant/award (A): 80,000 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Xenon Pharmaceuticals Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=XENE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →